Biotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More
Xconomy
JULY 29, 2016
Some observers’ minds instantly jumped to business —Gilead needs to pick up the acquisition pace to find its next big thing. After all, Gilead’s $11 billion purchase of Pharmasset in 2011, roundly jeered as an overpay at the time, brought it sofosbuvir. But our minds jumped to politics.
Let's personalize your content